Similarly, Canakinumab has been shown to have potent anti-cancer effects in a clinical trial [11], suggesting that targeting IL-1 may be an attractive therapeutic strategy for preventing/treating breast cancer-induced bone disease 1, [12,13]. Here, IL1B is linked to breast carcinoma.